Skip to main content

Latest

investment ideas
Deals, data buzz could help biotech shares exit Wall Street’s ‘no man’s land’
An employee at the Afrigen biotechnology company and Vaccine Hub facility, works in a laboratory in Cape Town, on Oct. 5.
report on business
Field Trip Health raises largest financing in Canada for a psychedelics company
This July 25, 2018 photo shows a vial of ketamine, which is normally stored in a locked cabinet, in Chicago. It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K. Now the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior. (AP Photo/Teresa Crawford)
report on business
B.C.’s Eupraxia Pharmaceuticals sees lacklustre trading debut
A TSX tote board is pictured in Toronto, on Dec. 31, 2012. THE CANADIAN PRESS/Frank Gunn
advisor etfs
Why the nascent psychedelics industry is getting investors’ attention
Psylocibin mushrooms growing in magic mushroom breads on an isolated plastic environment being collected by expert hands wearing white latex medical gloves. Fungi hallucinogen drugs production concept
report on business
First TSX-only biotech IPO in 18 years set for next week as Eupraxia closes books on $41-million offering
A TSX tote board is pictured in Toronto, on Dec.31, 2012. THE CANADIAN PRESS/Frank Gunn
report on business
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding
report on business
TMX CEO aims to encourage small biotech companies to list in Canada
A man works in the broadcast centre at the TMX Group Ltd. in Toronto, on May 9, 2014. THE CANADIAN PRESS/Darren Calabrese
report on business
RBC taps into biotech surge, investing in new Lumira venture fund
The RBC Royal Bank of Canada logo is seen in Halifax on Tuesday, April 2, 2019. Fourth-quarter results at Royal Bank of Canada edged lower compared with a year ago and fell short of analysts' expectations. THE CANADIAN PRESS/Andrew Vaughan
report on business
Vancouver’s Khosrowshahi family to launch US$400-million pharma IPO, capitalizing on biotech craze
 A TSX tote board is pictured in Toronto, on Dec. 31, 2012. THE CANADIAN PRESS/Frank Gunn
report on business
Rare milestone approaches for Canadian biotech sector as Aurinia awaits FDA OK to sell new drug
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. REUTERS/Jason Reed/File Photo
report on business
AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO
Carl Hansen, Director and CEO of AbCellera Biologics Inc., poses for a photograph in Vancouver, on Wednesday, December 2, 2020. Darryl Dyck/The Globe and Mail
opinion
What Canada needs to do to build a world-class biotech sector
Roberto Bellini
report on business
AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million
Preparing reagents for a molecular biology assay at AbCellera.
number cruncher
Which of these top 10 Canadian biotech stocks are undervalued?
For Number Cruncher column in Globe Investor/ROB only.
international business
AstraZeneca shares fall as investors react to $39-billion Alexion acquisition
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo
international business
AstraZeneca to buy U.S. drugmaker Alexion for $39-billion to expand in immunology
FILE PHOTO: An employee in personal protective equipment (PPE) removes vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine from a visual inspection machine inside a lab at Serum Institute of India, in Pune, India, November 30, 2020. REUTERS/Francis Mascarenhas/File Photo
report on business
Vancouver’s AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech
Preparing reagents for a molecular biology assay at AbCellera.
investment ideas
Cowen’s CEO sees gains in biotech, helped by easier access to cash
In this Nov. 16, 2020 file photo a man wearing a mask passes the New York Stock Exchange in New York.
report on business
Booming Canadian biotech sector on track for record year after raising $1-billion in venture capital so far in 2020
Universities have seen some of Canada’s most important discoveries.
report on business
Peter Thiel joins board of B.C. antibody therapy developer AbCellera in advance of expected IPO
NEW YORK, NY - NOVEMBER 01: Peter Thiel, Partner, Founders Fund, speaks at the New York Times DealBook conference on November 1, 2018 in New York City. (Photo by Stephanie Keith/Getty Images)
report on business
Canada’s Pascal Biosciences partners with U.S. firm to test cannabis-based cancer therapy
FILE - In this Aug. 15, 2019, file photo, marijuana grows at an indoor cannabis farm in Gardena, Calif. Laws legalizing recreational marijuana may lead to more traffic deaths, two new studies suggest, although questions remain about how they might influence driving habits. Previous research has had mixed results and the new studies, published Monday, June 22, 2020, in JAMA Internal Medicine, can’t prove that the traffic death increases they found were caused by marijuana use. (AP Photo/Richard Vogel, File)
report on business
Antibody therapy developer AbCellera hires banks for U.S. IPO, sources day
Antibody therapy developer AbCellera hires banks for U.S. IPO -sources
international business
Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal
(FILES) This file photo taken on March 27, 2020 shows a Sanofi's logo at the headquarters in Paris, during a strict lockdown in France aimed at curbing the spread of the COVID-19 infection, caused by the novel coronavirus. - French pharma giant Sanofi said August 17 it will buy US group Principia Biopharma for $3.68 billion in a deal that will boost its research and development into autoimmune and allergic diseases. (Photo by FRANCK FIFE / AFP) (Photo by FRANCK FIFE/AFP via Getty Images)
international business
CureVac doesn’t rule out accelerated approval for COVID-19 vaccine
FILE PHOTO: Professor Gottfried Kremsner injects a vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac to a volunteer at the start of a clinical test series at his tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach/File Photo
advisor mutual funds
Active management finds niche in post-pandemic market
Business Team Investment Entrepreneur Trading discussing and analysis graph stock market trading,stock chart concept
report on business
Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall
An AbCellera Biologics Inc. scientist operates AbCellera’s automated high-throughput screening platform at an AbCellera laboratory in this undated handout photo. As researchers race to develop a vaccine, the head of a Vancouver biotech company says another valuable shield against COVID-19 could work better and buy time in the interim. THE CANADIAN PRESS/HO, AbCellera Biologics Inc. *MANDATORY CREDIT*
stars and dogs
The Globe’s stars and dogs for the week
For Stars and Dogs column in Globe Investor/ROB only.
letters
July 9: ‘The government of the people, by Justin Trudeau, for the people.’ Readers take a closer look at the WE Charity contract, plus other letters to the editor
Prime Minister Justin Trudeau rises during a meeting of the Special Committee on the COVID-19 Pandemic in the House of Commons on Parliament Hill in Ottawa, on June 17, 2020.
streetwise newsletter
Streetwise newsletter: Best reads of the week
CEO of Shopify Tobias Lutke photographed in their Ottawa HQ, June 2019
report on business
Biotech blind spot: How Canada’s big investors missed the boom happening right now
7/3/20-Vancouver, B.C., Canada- Ali Tehrani is President and CEO of Zymeworks, a clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. -Alana Paterson for the Globe and Mail
inside the market
Top Canadian biotech investor on the firms most likely to turn COVID-19 drug trials into treatments and when a vaccine may arrive
FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
stars and dogs
The Globe’s stars and dogs for the week
science
BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial
BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial
european business
Temasek-led investor group makes $250-million vaccine bet on Germany’s BioNTech
MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. BioNTech and U.S. pharmaceutical giant Pfizer announced today that German authorities have granted them approval to begin clinical trials for BioNTech's BNT162, a possible vaccine against Covid-19. BioNTech will conduct the trial in Germany with 200 participants while Pfizer will conduct its trial in the United States once regulatory authorities grant the trial there. (Photo by Thomas Lohnes/Getty Images)
technology
Hamilton biotech Fusion sets IPO price at $17 a share for Friday debut on Nasdaq
FILE PHOTO: The Nasdaq logo is displayed at the Nasdaq Market site in New York September 2, 2015. REUTERS/Brendan McDermid